Women with breast cancer and endometriosis can finally breathe easier — the government’s advisory group has recommended triptorelin, a direct substitute for the soon-to-be-discontinued Zoladex, be added to the public subsidy list. With Zoladex’s withdrawal looming due to unsustainable pricing, patients faced life-altering decisions, including surgery, as they lost access to a vital treatment. Advocates warned of a dangerous two-tiered system unless a reliable alternative was secured. Now, with triptorelin approved for PBS listing, patients and doctors alike celebrate a stable, long-term solution — preventing future crises and reaffirming that patient care must always come first.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
